The economic burden of anemia in cancer patients receiving chemotherapy

Value in Health

Volumn 8, Issue 2, 2005, Pages 149-156

  Lyman, Gary H ^a,h   Berndt, Ernst R ^b   Kallich, Joel D ^c   Erder, M Haim ^d   Crown, William H ^e   Long, Stacey R ^f   Lee, Howard ^g   Song, Xue ^f   Finkelstein, Stan N ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c AMGEN INC   (United States)

^d Forest Pharmaceuticals Inc   (United States)

^e Ingenix Inc   (United States)

^f Medstat   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Anemia; Cancer; Cost of illness

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER INVASION; COST OF ILLNESS; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONEY; PARAMETER; PREDICTION; PRIORITY JOURNAL;

EID: 17144390180     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.03089.x     Document Type: Article

References (22)

1. Bailes JS. The economics of cancer care. Cancer 1995;76:1886-7.
2. Schuette HL, Tucker TC, Brown ML, et al. The costs of cancer care in the United States: implications for action. Oncol (Huntington) 1995;9(11 Suppl.):19-22.
3. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001;28(2 Suppl. 8):1-6.
4. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
5. Cremieux PY, Slavin MB, Fendrick M, et al. The costs of cancer: cancer-related conditions can add dramatically to overall costs of care. J Managed Care Med 2002;6:12-19.
6. Barnett A, Cremieux PY, Fendrick AM, et al. Anemia-related costs for cancer patients. J Managed Care Med 2002;6:20-8.
7. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson Comorbidity Index with administrative databases. J Clin Epidemiol 1996;49:1429-33.
8. Manning WG, Newhouse JP, Duan N, et al. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev 1987;77:251-77.
9. Duan N, Manning W, Morris C, et al. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983;1:115-26.
10. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78:605-10.
11. Mullahy J. Much ado about two: reconsidering transformation and the two-part model in health econometrics. J Health Econ 1998;17: 247-81.
12. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94.
13. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95.
14. Ai C, Norton E. Standard errors for the retransformation problem with heteroscedasticity. J Health Econ 2000;19:697-718.
15. Crown WH, Neslusen C, Russo PA, et al. Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health 2001;28:335-50.
16. Goodman AC, Nishiura E, Hankin JR. Short term drug abuse treatment costs and utilization: a multi-employer analysis. Med Care 1998;36:1214-27.
17. Oaxaca R, Ransom M. On discrimination and the decomposition of wage differentials. J Econometrics 1994;61:5-21.
18. Cotton J. On the decomposition of wage differentials. Rev Econ Stat 1988;70:236-43.
19. Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 2002;29(3 Suppl. 8):40-4.
20. Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002;29(3 Suppl. 8):45-54.
21. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34.
22. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with Epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.